Investor Presentation

15 Investor presentation First six months of 2022 Financial results - First six months of 2022 Novo NordiskⓇ In DKK million Sales Gross profit Gross margin Sales and distribution costs Percentage of sales First six months of 2022 First six Change Change 83,296 months of 2021 66,845 (reported) (CER) 25% 16% 70,310 84.4% (21,023) 25.2% 55,487 27% 17% 83.0% (16,257) 29% 22% 24.3% Research and development costs (10,329) (7,888) 31% 26% Percentage of sales 12.4% 11.8% Administration costs (1,961) (1,836) 7% 3% Percentage of sales 2.4% 2.7% Other operating income and expenses 541 255 112% 92% Operating profit 37,538 29,761 26% 14% Operating margin 45.1% 44.5% Financial items (net) (2,824) 1,094 Profit before income tax 34,714 30,855 13% Income taxes (7,186) (6,109) 18% Effective tax rate 20.7% 19.8% Net profit 27,528 24,746 11% Diluted earnings per share (DKK) 12.08 10.71 13% CER: Constant exchange rates

View entire presentation